We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cara Therapeutics

News List

Cara Therapeutics Submits NDA for KORSUVA Injection americanpharmaceuticalreview
December 31, 2020
Cara Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KORSUVA™ Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Cara Therapeutics Initiates Second Pruritus Phase 2 Trial of Peptelligence® americanpharmaceuticalreview
June 28, 2019
Enteris BioPharma congratulates Cara Therapeutics on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).
Cara Therapeutics Announces Proposed Offering of Common Stock firstwordpharma
March 30, 2017
Cara Therapeutics, Inc. (CARA)announced that it has commenced an underwritten public offering of $80 million of shares of its common stock.